J.P. Morgan Initiates Overweight Coverage on Neurogene
J.P. Morgan has initiated coverage of gene therapy developer Neurogene (NGNE) with an 'Overweight' recommendation, citing the company's lead program NGN-401 for Rett syndrome as a key driver. Analyst Priyanka Grover expressed optimism about Neurogene’s potential in addressing this rare neurodevelopmental disorder. The move comes at a time when investor interest is growing in gene therapy and orphan drug development, which could benefit the stock's performance. The recommendation reflects confidence in Neurogene's pipeline and its ability to capture market share within niche therapeutic areas.
Tickers: $NGNE
Topics: Gene Therapy Rett Syndrome Stock Coverage